Name | 2-[(5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)sulfanyl]-N-[3-(trifluoromethyl)phenyl]acetamide |
---|---|
Synonyms |
2-[(5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)sulfanyl]-N-[3-(trifluoromethyl)phenyl]acetamide
Acetamide, 2-[(5-methyl-5H-1,2,4-triazino[5,6-b]indol-3-yl)thio]-N-[3-(trifluoromethyl)phenyl]- |
Description | H1PVAT is a potent and selective inhibitor of poliovirus serotypes (PV-1, PV-2, PV-3), and inhibits early stage of the replication. H1PVAT interacts with viral capsid directly and protects PV against heat inactivation[1][2]. |
---|---|
Related Catalog | |
Target |
EC50: 10 nM (PV-1), 26 nM (PV-2), 218 nM (PV-3)[1] |
In Vitro | H1PVAT (10-218 nM; 24-48 h) inhibits poliovirus strain Sabin replication in a dose-dependent manner, with EC50s of 10 nM (PV-1), 26 nM (PV-2) and 218 nM (PV-3), respectively[1]. H1PVAT (30 min prior to or 1 h after PV-1 infection; 7 h) inhibits an early stage of viral replication , and only H1PVAT is administered prior to infection results reduction (>99.9%) in intracellular viral RNA levels[1]. H1PVAT (50 μM; 2 min) protects PV against heat inactivation with the 50% thermal inactivation temperature increased to 52.6 ℃ and 50.8 ℃, which suggests a direct interaction between the viral capsid and H1PVAT[1]. |
References |
[2]. Tijsma A. Antiviral strategies against polio and other enteroviruses. 2018. |
Density | 1.5±0.1 g/cm3 |
---|---|
Molecular Formula | C19H14F3N5OS |
Molecular Weight | 417.408 |
Exact Mass | 417.087128 |
LogP | 4.29 |
Index of Refraction | 1.674 |